Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Identifieur interne : 000952 ( PubMed/Checkpoint ); précédent : 000951; suivant : 000953Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Auteurs : Natalia Davydova ; Nicole C. Harris ; Sally Roufail ; Sophie Paquet-Fifield ; Musarat Ishaq ; Victor A. Streltsov ; Steven P. Williams ; Tara Karnezis ; Steven A. Stacker ; Marc G. AchenSource :
- The Journal of biological chemistry [ 1083-351X ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux, Anticorps neutralisants, Cellules cultivées, Derme (anatomopathologie), Derme (métabolisme), Endothélium vasculaire (anatomopathologie), Endothélium vasculaire (métabolisme), Facteur de croissance endothéliale vasculaire de type C (), Facteur de croissance endothéliale vasculaire de type C (génétique), Facteur de croissance endothéliale vasculaire de type C (métabolisme), Facteur de croissance endothéliale vasculaire de type D (), Facteur de croissance endothéliale vasculaire de type D (génétique), Facteur de croissance endothéliale vasculaire de type D (métabolisme), Femelle, Humains, Lymphangiogenèse, Mutagenèse dirigée, Mutation (génétique), Néovascularisation pathologique (anatomopathologie), Néovascularisation pathologique (métabolisme), Récepteur-2 au facteur croissance endothéliale vasculaire (génétique), Récepteur-2 au facteur croissance endothéliale vasculaire (métabolisme), Récepteur-3 au facteur croissance endothéliale vasculaire (génétique), Récepteur-3 au facteur croissance endothéliale vasculaire (métabolisme), Souris SCID, Souris de lignée NOD, Transduction du signal, Vaisseaux lymphatiques (anatomopathologie), Vaisseaux lymphatiques (métabolisme).
- MESH :
- anatomopathologie : Derme, Endothélium vasculaire, Néovascularisation pathologique, Vaisseaux lymphatiques.
- génétique : Facteur de croissance endothéliale vasculaire de type C, Facteur de croissance endothéliale vasculaire de type D, Mutation, Récepteur-2 au facteur croissance endothéliale vasculaire, Récepteur-3 au facteur croissance endothéliale vasculaire.
- métabolisme : Derme, Endothélium vasculaire, Facteur de croissance endothéliale vasculaire de type C, Facteur de croissance endothéliale vasculaire de type D, Néovascularisation pathologique, Récepteur-2 au facteur croissance endothéliale vasculaire, Récepteur-3 au facteur croissance endothéliale vasculaire, Vaisseaux lymphatiques.
- Animaux, Anticorps neutralisants, Cellules cultivées, Facteur de croissance endothéliale vasculaire de type C, Facteur de croissance endothéliale vasculaire de type D, Femelle, Humains, Lymphangiogenèse, Mutagenèse dirigée, Souris SCID, Souris de lignée NOD, Transduction du signal.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing, Cells, Cultured, Dermis (metabolism), Dermis (pathology), Endothelium, Vascular (metabolism), Endothelium, Vascular (pathology), Female, Humans, Lymphangiogenesis, Lymphatic Vessels (metabolism), Lymphatic Vessels (pathology), Mice, Inbred NOD, Mice, SCID, Mutagenesis, Site-Directed, Mutation (genetics), Neovascularization, Pathologic (metabolism), Neovascularization, Pathologic (pathology), Signal Transduction, Vascular Endothelial Growth Factor C (chemistry), Vascular Endothelial Growth Factor C (genetics), Vascular Endothelial Growth Factor C (metabolism), Vascular Endothelial Growth Factor D (chemistry), Vascular Endothelial Growth Factor D (genetics), Vascular Endothelial Growth Factor D (metabolism), Vascular Endothelial Growth Factor Receptor-2 (genetics), Vascular Endothelial Growth Factor Receptor-2 (metabolism), Vascular Endothelial Growth Factor Receptor-3 (genetics), Vascular Endothelial Growth Factor Receptor-3 (metabolism).
- MESH :
- chemical , chemistry : Vascular Endothelial Growth Factor C, Vascular Endothelial Growth Factor D.
- chemical , genetics : Vascular Endothelial Growth Factor C, Vascular Endothelial Growth Factor D, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor Receptor-3.
- chemical , metabolism : Vascular Endothelial Growth Factor C, Vascular Endothelial Growth Factor D, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor Receptor-3.
- chemical : Antibodies, Neutralizing.
- genetics : Mutation.
- metabolism : Dermis, Endothelium, Vascular, Lymphatic Vessels, Neovascularization, Pathologic.
- pathology : Dermis, Endothelium, Vascular, Lymphatic Vessels, Neovascularization, Pathologic.
- Animals, Cells, Cultured, Female, Humans, Lymphangiogenesis, Mice, Inbred NOD, Mice, SCID, Mutagenesis, Site-Directed, Signal Transduction.
Abstract
VEGF-C and VEGF-D are secreted glycoproteins that induce angiogenesis and lymphangiogenesis in cancer, thereby promoting tumor growth and spread. They exhibit structural homology and activate VEGFR-2 and VEGFR-3, receptors on endothelial cells that signal for growth of blood vessels and lymphatics. VEGF-C and VEGF-D were thought to exhibit similar bioactivities, yet recent studies indicated distinct signaling mechanisms (e.g. tumor-derived VEGF-C promoted expression of the prostaglandin biosynthetic enzyme COX-2 in lymphatics, a response thought to facilitate metastasis via the lymphatic vasculature, whereas VEGF-D did not). Here we explore the basis of the distinct bioactivities of VEGF-D using a neutralizing antibody, peptide mapping, and mutagenesis to demonstrate that the N-terminal α-helix of mature VEGF-D (Phe(93)-Arg(108)) is critical for binding VEGFR-2 and VEGFR-3. Importantly, the N-terminal part of this α-helix, from Phe(93) to Thr(98), is required for binding VEGFR-3 but not VEGFR-2. Surprisingly, the corresponding part of the α-helix in mature VEGF-C did not influence binding to either VEGFR-2 or VEGFR-3, indicating distinct determinants of receptor binding by these growth factors. A variant of mature VEGF-D harboring a mutation in the N-terminal α-helix, D103A, exhibited enhanced potency for activating VEGFR-3, was able to promote increased COX-2 mRNA levels in lymphatic endothelial cells, and had enhanced capacity to induce lymphatic sprouting in vivo This mutant may be useful for developing protein-based therapeutics to drive lymphangiogenesis in clinical settings, such as lymphedema. Our studies shed light on the VEGF-D structure/function relationship and provide a basis for understanding functional differences compared with VEGF-C.
DOI: 10.1074/jbc.M116.736801
PubMed: 27852824
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:27852824Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.</title>
<author><name sortKey="Davydova, Natalia" sort="Davydova, Natalia" uniqKey="Davydova N" first="Natalia" last="Davydova">Natalia Davydova</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Harris, Nicole C" sort="Harris, Nicole C" uniqKey="Harris N" first="Nicole C" last="Harris">Nicole C. Harris</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Roufail, Sally" sort="Roufail, Sally" uniqKey="Roufail S" first="Sally" last="Roufail">Sally Roufail</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Paquet Fifield, Sophie" sort="Paquet Fifield, Sophie" uniqKey="Paquet Fifield S" first="Sophie" last="Paquet-Fifield">Sophie Paquet-Fifield</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Ishaq, Musarat" sort="Ishaq, Musarat" uniqKey="Ishaq M" first="Musarat" last="Ishaq">Musarat Ishaq</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Streltsov, Victor A" sort="Streltsov, Victor A" uniqKey="Streltsov V" first="Victor A" last="Streltsov">Victor A. Streltsov</name>
<affiliation><nlm:affiliation>the Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, Parkville, Victoria 3052, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Williams, Steven P" sort="Williams, Steven P" uniqKey="Williams S" first="Steven P" last="Williams">Steven P. Williams</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Karnezis, Tara" sort="Karnezis, Tara" uniqKey="Karnezis T" first="Tara" last="Karnezis">Tara Karnezis</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Stacker, Steven A" sort="Stacker, Steven A" uniqKey="Stacker S" first="Steven A" last="Stacker">Steven A. Stacker</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Achen, Marc G" sort="Achen, Marc G" uniqKey="Achen M" first="Marc G" last="Achen">Marc G. Achen</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, marc.achen@petermac.org.</nlm:affiliation>
<wicri:noCountry code="subField">marc.achen@petermac.org.</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27852824</idno>
<idno type="pmid">27852824</idno>
<idno type="doi">10.1074/jbc.M116.736801</idno>
<idno type="wicri:Area/PubMed/Corpus">000516</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000516</idno>
<idno type="wicri:Area/PubMed/Curation">000516</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000516</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000516</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000516</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.</title>
<author><name sortKey="Davydova, Natalia" sort="Davydova, Natalia" uniqKey="Davydova N" first="Natalia" last="Davydova">Natalia Davydova</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Harris, Nicole C" sort="Harris, Nicole C" uniqKey="Harris N" first="Nicole C" last="Harris">Nicole C. Harris</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Roufail, Sally" sort="Roufail, Sally" uniqKey="Roufail S" first="Sally" last="Roufail">Sally Roufail</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Paquet Fifield, Sophie" sort="Paquet Fifield, Sophie" uniqKey="Paquet Fifield S" first="Sophie" last="Paquet-Fifield">Sophie Paquet-Fifield</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Ishaq, Musarat" sort="Ishaq, Musarat" uniqKey="Ishaq M" first="Musarat" last="Ishaq">Musarat Ishaq</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Streltsov, Victor A" sort="Streltsov, Victor A" uniqKey="Streltsov V" first="Victor A" last="Streltsov">Victor A. Streltsov</name>
<affiliation><nlm:affiliation>the Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, Parkville, Victoria 3052, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Williams, Steven P" sort="Williams, Steven P" uniqKey="Williams S" first="Steven P" last="Williams">Steven P. Williams</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Karnezis, Tara" sort="Karnezis, Tara" uniqKey="Karnezis T" first="Tara" last="Karnezis">Tara Karnezis</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Stacker, Steven A" sort="Stacker, Steven A" uniqKey="Stacker S" first="Steven A" last="Stacker">Steven A. Stacker</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</nlm:affiliation>
<wicri:noCountry code="subField">Victoria 3000</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Achen, Marc G" sort="Achen, Marc G" uniqKey="Achen M" first="Marc G" last="Achen">Marc G. Achen</name>
<affiliation><nlm:affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, marc.achen@petermac.org.</nlm:affiliation>
<wicri:noCountry code="subField">marc.achen@petermac.org.</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of biological chemistry</title>
<idno type="eISSN">1083-351X</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Neutralizing</term>
<term>Cells, Cultured</term>
<term>Dermis (metabolism)</term>
<term>Dermis (pathology)</term>
<term>Endothelium, Vascular (metabolism)</term>
<term>Endothelium, Vascular (pathology)</term>
<term>Female</term>
<term>Humans</term>
<term>Lymphangiogenesis</term>
<term>Lymphatic Vessels (metabolism)</term>
<term>Lymphatic Vessels (pathology)</term>
<term>Mice, Inbred NOD</term>
<term>Mice, SCID</term>
<term>Mutagenesis, Site-Directed</term>
<term>Mutation (genetics)</term>
<term>Neovascularization, Pathologic (metabolism)</term>
<term>Neovascularization, Pathologic (pathology)</term>
<term>Signal Transduction</term>
<term>Vascular Endothelial Growth Factor C (chemistry)</term>
<term>Vascular Endothelial Growth Factor C (genetics)</term>
<term>Vascular Endothelial Growth Factor C (metabolism)</term>
<term>Vascular Endothelial Growth Factor D (chemistry)</term>
<term>Vascular Endothelial Growth Factor D (genetics)</term>
<term>Vascular Endothelial Growth Factor D (metabolism)</term>
<term>Vascular Endothelial Growth Factor Receptor-2 (genetics)</term>
<term>Vascular Endothelial Growth Factor Receptor-2 (metabolism)</term>
<term>Vascular Endothelial Growth Factor Receptor-3 (genetics)</term>
<term>Vascular Endothelial Growth Factor Receptor-3 (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps neutralisants</term>
<term>Cellules cultivées</term>
<term>Derme (anatomopathologie)</term>
<term>Derme (métabolisme)</term>
<term>Endothélium vasculaire (anatomopathologie)</term>
<term>Endothélium vasculaire (métabolisme)</term>
<term>Facteur de croissance endothéliale vasculaire de type C ()</term>
<term>Facteur de croissance endothéliale vasculaire de type C (génétique)</term>
<term>Facteur de croissance endothéliale vasculaire de type C (métabolisme)</term>
<term>Facteur de croissance endothéliale vasculaire de type D ()</term>
<term>Facteur de croissance endothéliale vasculaire de type D (génétique)</term>
<term>Facteur de croissance endothéliale vasculaire de type D (métabolisme)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphangiogenèse</term>
<term>Mutagenèse dirigée</term>
<term>Mutation (génétique)</term>
<term>Néovascularisation pathologique (anatomopathologie)</term>
<term>Néovascularisation pathologique (métabolisme)</term>
<term>Récepteur-2 au facteur croissance endothéliale vasculaire (génétique)</term>
<term>Récepteur-2 au facteur croissance endothéliale vasculaire (métabolisme)</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire (génétique)</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire (métabolisme)</term>
<term>Souris SCID</term>
<term>Souris de lignée NOD</term>
<term>Transduction du signal</term>
<term>Vaisseaux lymphatiques (anatomopathologie)</term>
<term>Vaisseaux lymphatiques (métabolisme)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term>
<term>Vascular Endothelial Growth Factor D</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term>
<term>Vascular Endothelial Growth Factor D</term>
<term>Vascular Endothelial Growth Factor Receptor-2</term>
<term>Vascular Endothelial Growth Factor Receptor-3</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term>
<term>Vascular Endothelial Growth Factor D</term>
<term>Vascular Endothelial Growth Factor Receptor-2</term>
<term>Vascular Endothelial Growth Factor Receptor-3</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Neutralizing</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Derme</term>
<term>Endothélium vasculaire</term>
<term>Néovascularisation pathologique</term>
<term>Vaisseaux lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Mutation</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type C</term>
<term>Facteur de croissance endothéliale vasculaire de type D</term>
<term>Mutation</term>
<term>Récepteur-2 au facteur croissance endothéliale vasculaire</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dermis</term>
<term>Endothelium, Vascular</term>
<term>Lymphatic Vessels</term>
<term>Neovascularization, Pathologic</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Derme</term>
<term>Endothélium vasculaire</term>
<term>Facteur de croissance endothéliale vasculaire de type C</term>
<term>Facteur de croissance endothéliale vasculaire de type D</term>
<term>Néovascularisation pathologique</term>
<term>Récepteur-2 au facteur croissance endothéliale vasculaire</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire</term>
<term>Vaisseaux lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Dermis</term>
<term>Endothelium, Vascular</term>
<term>Lymphatic Vessels</term>
<term>Neovascularization, Pathologic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cells, Cultured</term>
<term>Female</term>
<term>Humans</term>
<term>Lymphangiogenesis</term>
<term>Mice, Inbred NOD</term>
<term>Mice, SCID</term>
<term>Mutagenesis, Site-Directed</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Anticorps neutralisants</term>
<term>Cellules cultivées</term>
<term>Facteur de croissance endothéliale vasculaire de type C</term>
<term>Facteur de croissance endothéliale vasculaire de type D</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphangiogenèse</term>
<term>Mutagenèse dirigée</term>
<term>Souris SCID</term>
<term>Souris de lignée NOD</term>
<term>Transduction du signal</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">VEGF-C and VEGF-D are secreted glycoproteins that induce angiogenesis and lymphangiogenesis in cancer, thereby promoting tumor growth and spread. They exhibit structural homology and activate VEGFR-2 and VEGFR-3, receptors on endothelial cells that signal for growth of blood vessels and lymphatics. VEGF-C and VEGF-D were thought to exhibit similar bioactivities, yet recent studies indicated distinct signaling mechanisms (e.g. tumor-derived VEGF-C promoted expression of the prostaglandin biosynthetic enzyme COX-2 in lymphatics, a response thought to facilitate metastasis via the lymphatic vasculature, whereas VEGF-D did not). Here we explore the basis of the distinct bioactivities of VEGF-D using a neutralizing antibody, peptide mapping, and mutagenesis to demonstrate that the N-terminal α-helix of mature VEGF-D (Phe(93)-Arg(108)) is critical for binding VEGFR-2 and VEGFR-3. Importantly, the N-terminal part of this α-helix, from Phe(93) to Thr(98), is required for binding VEGFR-3 but not VEGFR-2. Surprisingly, the corresponding part of the α-helix in mature VEGF-C did not influence binding to either VEGFR-2 or VEGFR-3, indicating distinct determinants of receptor binding by these growth factors. A variant of mature VEGF-D harboring a mutation in the N-terminal α-helix, D103A, exhibited enhanced potency for activating VEGFR-3, was able to promote increased COX-2 mRNA levels in lymphatic endothelial cells, and had enhanced capacity to induce lymphatic sprouting in vivo This mutant may be useful for developing protein-based therapeutics to drive lymphangiogenesis in clinical settings, such as lymphedema. Our studies shed light on the VEGF-D structure/function relationship and provide a basis for understanding functional differences compared with VEGF-C.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27852824</PMID>
<DateCreated><Year>2016</Year>
<Month>11</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>07</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>07</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>291</Volume>
<Issue>53</Issue>
<PubDate><Year>2016</Year>
<Month>Dec</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.</ArticleTitle>
<Pagination><MedlinePgn>27265-27278</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M116.736801</ELocationID>
<Abstract><AbstractText>VEGF-C and VEGF-D are secreted glycoproteins that induce angiogenesis and lymphangiogenesis in cancer, thereby promoting tumor growth and spread. They exhibit structural homology and activate VEGFR-2 and VEGFR-3, receptors on endothelial cells that signal for growth of blood vessels and lymphatics. VEGF-C and VEGF-D were thought to exhibit similar bioactivities, yet recent studies indicated distinct signaling mechanisms (e.g. tumor-derived VEGF-C promoted expression of the prostaglandin biosynthetic enzyme COX-2 in lymphatics, a response thought to facilitate metastasis via the lymphatic vasculature, whereas VEGF-D did not). Here we explore the basis of the distinct bioactivities of VEGF-D using a neutralizing antibody, peptide mapping, and mutagenesis to demonstrate that the N-terminal α-helix of mature VEGF-D (Phe(93)-Arg(108)) is critical for binding VEGFR-2 and VEGFR-3. Importantly, the N-terminal part of this α-helix, from Phe(93) to Thr(98), is required for binding VEGFR-3 but not VEGFR-2. Surprisingly, the corresponding part of the α-helix in mature VEGF-C did not influence binding to either VEGFR-2 or VEGFR-3, indicating distinct determinants of receptor binding by these growth factors. A variant of mature VEGF-D harboring a mutation in the N-terminal α-helix, D103A, exhibited enhanced potency for activating VEGFR-3, was able to promote increased COX-2 mRNA levels in lymphatic endothelial cells, and had enhanced capacity to induce lymphatic sprouting in vivo This mutant may be useful for developing protein-based therapeutics to drive lymphangiogenesis in clinical settings, such as lymphedema. Our studies shed light on the VEGF-D structure/function relationship and provide a basis for understanding functional differences compared with VEGF-C.</AbstractText>
<CopyrightInformation>© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davydova</LastName>
<ForeName>Natalia</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Harris</LastName>
<ForeName>Nicole C</ForeName>
<Initials>NC</Initials>
<AffiliationInfo><Affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Roufail</LastName>
<ForeName>Sally</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Paquet-Fifield</LastName>
<ForeName>Sophie</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ishaq</LastName>
<ForeName>Musarat</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Streltsov</LastName>
<ForeName>Victor A</ForeName>
<Initials>VA</Initials>
<AffiliationInfo><Affiliation>the Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, Parkville, Victoria 3052, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Williams</LastName>
<ForeName>Steven P</ForeName>
<Initials>SP</Initials>
<AffiliationInfo><Affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Karnezis</LastName>
<ForeName>Tara</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stacker</LastName>
<ForeName>Steven A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo><Affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>the Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3010, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Achen</LastName>
<ForeName>Marc G</ForeName>
<Initials>MG</Initials>
<AffiliationInfo><Affiliation>From the Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, marc.achen@petermac.org.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>the Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3010, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName>
<AccessionNumberList><AccessionNumber>2XV7</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>11</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467486">VEGFC protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C579459">VEGFD protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042582">Vascular Endothelial Growth Factor C</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042643">Vascular Endothelial Growth Factor D</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040321">Vascular Endothelial Growth Factor Receptor-3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Vis Exp. 2016 Mar 15;(109 ):null</RefSource>
<PMID Version="1">27022756</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Med. 2001 Sep;7(9):598-608</RefSource>
<PMID Version="1">11778649</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>EMBO J. 2001 Feb 15;20(4):672-82</RefSource>
<PMID Version="1">11179212</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2014 Sep;124(9):3901-12</RefSource>
<PMID Version="1">25133426</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2009 Jun 5;104(11):1302-12</RefSource>
<PMID Version="1">19443835</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Development. 2014 Mar;141(6):1239-49</RefSource>
<PMID Version="1">24523457</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2002 Sep 16;196(6):719-30</RefSource>
<PMID Version="1">12235206</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Biochem. 2000 May;267(9):2505-15</RefSource>
<PMID Version="1">10785369</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Surg Res. 2015 Jun 1;196(1):200-7</RefSource>
<PMID Version="1">25777822</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2003 Jan 27;88(2):237-44</RefSource>
<PMID Version="1">12610509</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2007 Apr;21(4):1003-12</RefSource>
<PMID Version="1">17210781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2011 Mar 29;123(12):1335-51</RefSource>
<PMID Version="1">21444892</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 Mar 27;123(13):2000-7</RefSource>
<PMID Version="1">24523239</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Opin Cell Biol. 2010 Oct;22(5):617-25</RefSource>
<PMID Version="1">20817428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2012 Feb 14;21(2):181-95</RefSource>
<PMID Version="1">22340592</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Mol Biol. 2011 Apr 8;407(4):581-93</RefSource>
<PMID Version="1">21315726</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 2013 Aug;133(8):2074-84</RefSource>
<PMID Version="1">23439394</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2005 Jun 1;65(11):4739-46</RefSource>
<PMID Version="1">15930292</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12677-82</RefSource>
<PMID Version="1">11592985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2003 Jun;111(11):1723-32</RefSource>
<PMID Version="1">12782675</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Angiogenesis. 2015 Jul;18(3):313-26</RefSource>
<PMID Version="1">26018927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1999 Nov 5;274(45):32127-36</RefSource>
<PMID Version="1">10542248</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Apr 28;117(17):4667-78</RefSource>
<PMID Version="1">21364190</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Chin J Cancer. 2013 Jun;32(6):297-302</RefSource>
<PMID Version="1">23419196</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2001 Aug 1;92(3):556-68</RefSource>
<PMID Version="1">11505400</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2001 Jun 1;276(22):19166-71</RefSource>
<PMID Version="1">11279005</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 2013 May;257(5):961-7</RefSource>
<PMID Version="1">23013803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Feb 1;109(3):1010-7</RefSource>
<PMID Version="1">17032920</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Opin Cell Biol. 2009 Apr;21(2):154-65</RefSource>
<PMID Version="1">19230644</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2014 Mar;14(3):159-72</RefSource>
<PMID Version="1">24561443</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 Feb 13;123(7):1102-12</RefSource>
<PMID Version="1">24269955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Res. 2014 Aug;2(8):701-7</RefSource>
<PMID Version="1">25092811</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2002 Jun 5;94(11):819-25</RefSource>
<PMID Version="1">12048269</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2001 Feb;7(2):192-8</RefSource>
<PMID Version="1">11175850</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2014 May 13;129(19):1962-71</RefSource>
<PMID Version="1">24552833</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>EMBO Rep. 2004 Jan;5(1):78-84</RefSource>
<PMID Version="1">14710191</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2007 Apr;21(4):1088-98</RefSource>
<PMID Version="1">17242158</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2007 Jun 11;204(6):1431-40</RefSource>
<PMID Version="1">17535974</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2003 Sep 26;278(39):38004-14</RefSource>
<PMID Version="1">12867434</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2007 Dec;13(12):1458-66</RefSource>
<PMID Version="1">18059280</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gene. 2013 Aug 10;525(2):217-9</RefSource>
<PMID Version="1">23608170</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>EMBO J. 1996 Jan 15;15(2):290-98</RefSource>
<PMID Version="1">8617204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2013 Jul 15;73(14):4212-21</RefSource>
<PMID Version="1">23695550</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>APMIS. 2004 Jul-Aug;112(7-8):539-49</RefSource>
<PMID Version="1">15563315</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Feb 3;117(5):1507-15</RefSource>
<PMID Version="1">21148085</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2005 Feb;7(2):121-7</RefSource>
<PMID Version="1">15710325</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2001 Feb;7(2):186-91</RefSource>
<PMID Version="1">11175849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2014 Mar;124(3):878-87</RefSource>
<PMID Version="1">24590272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2009 Jun 5;284(23):16037-48</RefSource>
<PMID Version="1">19366703</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Methods. 2012 Jun 28;9(7):676-82</RefSource>
<PMID Version="1">22743772</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Growth Factors. 2012 Oct;30(5):283-96</RefSource>
<PMID Version="1">22817635</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2011 Aug;25(8):2615-25</RefSource>
<PMID Version="1">21515745</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2425-30</RefSource>
<PMID Version="1">20145116</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>EMBO J. 1997 Jul 1;16(13):3898-911</RefSource>
<PMID Version="1">9233800</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Protein Expr Purif. 2012 Mar;82(1):232-9</RefSource>
<PMID Version="1">22261343</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 2009 May;129(5):1292-8</RefSource>
<PMID Version="1">19005491</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell. 2010 Feb 19;140(4):460-76</RefSource>
<PMID Version="1">20178740</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2002 Jul;16(9):922-34</RefSource>
<PMID Version="1">12087053</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2014 Jan 14;53(1):7-9</RefSource>
<PMID Version="1">24354278</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pathol. 2016 Jun;239(2):152-61</RefSource>
<PMID Version="1">26924464</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53</RefSource>
<PMID Version="1">9435229</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2010 Sep 27;207(10):2255-69</RefSource>
<PMID Version="1">20837699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Rep. 2012 Mar 29;1(3):191-9</RefSource>
<PMID Version="1">22832193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2003 Sep 15;198(6):863-8</RefSource>
<PMID Version="1">12963694</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):12960-5</RefSource>
<PMID Version="1">23878260</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2013 Mar 22;288(12):8176-86</RefSource>
<PMID Version="1">23404505</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2001 Mar 1;61(5):1786-90</RefSource>
<PMID Version="1">11280723</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2001 Nov 23;276(47):44307-14</RefSource>
<PMID Version="1">11574540</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020405" MajorTopicYN="N">Dermis</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D042583" MajorTopicYN="Y">Lymphangiogenesis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D042582" MajorTopicYN="N">Vascular Endothelial Growth Factor C</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D042643" MajorTopicYN="N">Vascular Endothelial Growth Factor D</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D040301" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-2</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D040321" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-3</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angiogenesis</Keyword>
<Keyword MajorTopicYN="N">endothelial cell</Keyword>
<Keyword MajorTopicYN="N">lymphangiogenesis</Keyword>
<Keyword MajorTopicYN="N">mutagenesis in vitro</Keyword>
<Keyword MajorTopicYN="N">receptor</Keyword>
<Keyword MajorTopicYN="N">vascular endothelial growth factor (VEGF)</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>09</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>11</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>11</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>7</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>11</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27852824</ArticleId>
<ArticleId IdType="pii">M116.736801</ArticleId>
<ArticleId IdType="doi">10.1074/jbc.M116.736801</ArticleId>
<ArticleId IdType="pmc">PMC5207153</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Achen, Marc G" sort="Achen, Marc G" uniqKey="Achen M" first="Marc G" last="Achen">Marc G. Achen</name>
<name sortKey="Davydova, Natalia" sort="Davydova, Natalia" uniqKey="Davydova N" first="Natalia" last="Davydova">Natalia Davydova</name>
<name sortKey="Harris, Nicole C" sort="Harris, Nicole C" uniqKey="Harris N" first="Nicole C" last="Harris">Nicole C. Harris</name>
<name sortKey="Ishaq, Musarat" sort="Ishaq, Musarat" uniqKey="Ishaq M" first="Musarat" last="Ishaq">Musarat Ishaq</name>
<name sortKey="Karnezis, Tara" sort="Karnezis, Tara" uniqKey="Karnezis T" first="Tara" last="Karnezis">Tara Karnezis</name>
<name sortKey="Paquet Fifield, Sophie" sort="Paquet Fifield, Sophie" uniqKey="Paquet Fifield S" first="Sophie" last="Paquet-Fifield">Sophie Paquet-Fifield</name>
<name sortKey="Roufail, Sally" sort="Roufail, Sally" uniqKey="Roufail S" first="Sally" last="Roufail">Sally Roufail</name>
<name sortKey="Stacker, Steven A" sort="Stacker, Steven A" uniqKey="Stacker S" first="Steven A" last="Stacker">Steven A. Stacker</name>
<name sortKey="Streltsov, Victor A" sort="Streltsov, Victor A" uniqKey="Streltsov V" first="Victor A" last="Streltsov">Victor A. Streltsov</name>
<name sortKey="Williams, Steven P" sort="Williams, Steven P" uniqKey="Williams S" first="Steven P" last="Williams">Steven P. Williams</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000952 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000952 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:27852824 |texte= Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:27852824" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |